Tendon Regeneration, Skin Rejuvenation and
Dermal Injector Patents Granted in the
United States, Europe,
South Africa, Hong Kong, China, and Japan
VANCOUVER, April 16, 2019 /CNW/ - RepliCel Life Sciences
Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the
"Company"), a company developing next-generation technologies in
aesthetics and orthopedics, is pleased to announce it has
recently received notifications of several patents issued, allowed,
and granted to the Company from Europe, China, Hong
Kong, Japan, the United States and South Africa. These relate to three of the
distinct patent families RepliCel continues to prosecute around the
world.
The first group of patents relates to compositions and
methods of RepliCel's technology to treat and repair
tendons. A patent has been granted in Europe (Patent No.
2956543), in China (Patent No.
ZL201480011232.2), in Russia
(Patent No. 2678878), and will be granted April 30th in the United States under Patent No. 10272118.
These patents pertain to the Company's non-bulbar dermal
sheath cup cell technology and the methods used in employing that
cell therapy for the treatment of chronically damaged tendons.
This technology has been the subject of successful initial
clinical evaluation in chronic Achilles tendinopathy. The Company
intends to pursue next-phase clinical testing and commercial launch
of the product in Japan while at
the same time co-developing it in Greater
China with its partner, YOFOTO (China) Health Co.
Three patents were also recently granted in RepliCel's patent
family related to its dermal injection technology. European patent
No 2809381 was recently granted in Hong
Kong and a patent granted in both China (Patent No. ZL201380018521) and
Japan (Patent No. 6280052).
RepliCel's dermal injector is the Company's nearest-term
commercial asset expected to be approved for market launch next
year in Europe and all other
countries accepting such CE Marks including Hong Kong. RepliCel's partner, YOFOTO holds
the license to market the injector in Hong Kong where it plans to launch the product
immediately upon registering the CE mark there.
The final patent recently granted to RepliCel is within the
Company's patent family related to compositions and methods for
treating skin. This patent was granted in South Africa (Patent No. 2016/00351).
The patent relates to the Company's non-bulbar dermal sheath cup
cell technology and the methods used in employing that cell therapy
for the treatment of sun-damaged and aging skin. This technology
has been the subject of successful initial clinical evaluation in
Germany. The Company intends to
pursue next-phase clinical testing and commercial launch of the
product in Japan while at the same
time co-developing it in Greater
China with its partner, YOFOTO (China) Health Co.
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing cell therapies
for aesthetic and orthopedic conditions affecting what the Company
believes is approximately one in three people in industrialized
nations, including aging/sun-damaged skin, pattern baldness, and
chronic tendon degeneration. These conditions, often
associated with aging, are caused by a deficit of healthy cells
required for normal tissue healing and function. These cell therapy
product candidates are based on RepliCel's innovative technology,
utilizing cell populations isolated from a patient's healthy hair
follicles.
The Company's product pipeline is comprised of RCT-01 for tendon
repair, RCS-01 for skin rejuvenation, and RCH-01 for hair
restoration. RCH-01 is exclusively licensed in Asia to Shiseido Company. RepliCel and
Shiseido are currently co-developing the product in Japan. RepliCel maintains the rights to RCH-01
for the rest of the world. RCT-01 and RCS-01 are exclusively
licensed in Greater China to
YOFOTO (China) Health Company.
RepliCel and YOFOTO are currently co-developing these products in
China. RepliCel maintains the
rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device,
RCI-02, and related consumables, which is expected to improve the
administration of its cell therapy products and certain other
injectables. YOFOTO has exclusively licensed the commercial rights
for the RCI-02 device and consumables in Greater China for dermatology applications and
is expected to first launch the product in Hong Kong upon it being CE marked. Please
visit www.replicel.com for additional information.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/replicel-secures-several-new-patents-for-its-regenerative-medicine-technologies-300832509.html
SOURCE RepliCel Life Sciences Inc.